Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

A new cohort study included 778 men with prostate cancer who had received either radiation or surgery within 1 year of diagnosis. Patients who lived in rural areas had nearly twice the rate of ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Extended pelvic lymph node dissection prolongs biochemical recurrence-free and metastasis-free survivals in localized prostate cancer.

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...